IRD - Opus Genetics, Inc.

Insider Purchase by Gallagher Cam (Dir)

Stock Price (After Trade)
Stock Price (Before Trade)

Loading data...

Trade Summary

3 days ago, Gallagher Cam, serving as Dir at Opus Genetics, Inc. (IRD), purchased 164,000 shares at $1.97 per share, for a total transaction value of $323,693.00. Following this transaction, Gallagher Cam now holds 2,007,430 shares of IRD.

This purchase represents a 9.00% increase in Gallagher Cam's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, December 29, 2025 and publicly disclosed via SEC Form 4 filing on Wednesday, December 31, 2025, 2 days after the trade was made.

Opus Genetics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Gallagher Cam

Gallagher Cam

Dir

Cam Gallagher, MBA, is a seasoned biotechnology executive with over 30 years of experience in the life sciences industry, specializing in new company formation, corporate development, marketing, operations, and early-stage investing.[[1]](https://opusgtx.com/team/cam-gallagher-mba/)[[2]](https://www.xlinktx.com/team-members/cam-gallagher-mba/) He currently serves as President and CEO of Alessa Therapeutics, a clinical-stage drug development company focused on localized drug delivery for prostate cancer, and as a board member for Opus Genetics, Inc. (NASDAQ: IRD), where he has been a director since January 2019 and Chair since December 2019; he also sits on the boards of SelectION, Immusoft, and UC San Diego Moores Cancer Center.[[1]](https://opusgtx.com/team/cam-gallagher-mba/)[[2]](https://www.xlinktx.com/team-members/cam-gallagher-mba/)[[4]](https://ir.opusgtx.com/corporate-governance)[[5]](https://opusgtx.com/about/board-of-directors/) Gallagher's career highlights include co-founding and serving as President and board member of Zentalis Pharmaceuticals (NASDAQ: ZNTL) from 2014 to 2024, Chief Business Officer at RetroSense Therapeutics (acquired by Allergan in 2016), and founding board member at VelosBio (acquired by Merck for $2.8B in 2020).[[1]](https://opusgtx.com/team/cam-gallagher-mba/)[[2]](https://www.xlinktx.com/team-members/cam-gallagher-mba/) He co-founded Nerveda, LLC, a life science seed fund, and held management roles at Oncternal, Zavante, Verus Pharma, CV Therapeutics, and Dura Pharma. Gallagher recently purchased 83,000 shares of Opus Genetics stock on December 29, 2025, at $1.97 per share, signaling confidence in the company.[[3]](https://www.marketbeat.com/instant-alerts/opus-genetics-nasdaqird-director-cam-gallagher-purchases-83000-shares-2025-12-31/) He holds an MBA from the University of San Diego and a BS (or BBA) in Business Administration from Ohio University.[[1]](https://opusgtx.com/team/cam-gallagher-mba/)[[2]](https://www.xlinktx.com/team-members/cam-gallagher-mba/)

View full insider profile →

Trade Price

$1.97

Quantity

164,000

Total Value

$323,693.00

Shares Owned

2,007,430

Trade Date

Monday, December 29, 2025

3 days ago

SEC Filing Date

Wednesday, December 31, 2025

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Opus Genetics, Inc.

Company Overview

No company information available
View news mentioning IRD

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/2709875

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime